According to a new market report published by Transparency Market Research Heparin Market - Europe Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2022” the Europe heparin market was valued at USD 2,004.5 million in 2013 and is estimated to reach USD 3,148.0 million by 2022 growing with a CAGR of 5.2% from 2014 to 2022.
Browse the full Heparin Market (Unfractionated Heparin, Low Molecular Weight Heparin & Ultra Low Molecular Weight Heparin) - Europe Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 report at http://www.transparencymarketresearch.com/europe-heparin-market.html
The heparin market in Europe has been categorized into major national markets namely, the United Kingdom, Germany, Spain, Italy, France, and Rest of Europe. The European market is among the major contributors to the global heparin market owing to its developed economy and high prevalence of coagulation disorders. In the current scenario, according to the 2015 Ageing Report by the European Commission, the percentage of population aged above 65 years is expected to increase from 21% in 2013 to 32% in 2060. As aging is proportional to increasing incidences of VTE diseases such as deep vein thrombosis (DVT) and pulmonary embolism (PE) demand for heparin is expected to increase in coming years.
Germany accounts for the largest market share in the overall Europe heparin market accounting for around 274.8 million in 2013. Key attributes to the market growth in Germany encompasses burgeoning population of venous thromboembolism (VTE) patients owing to which the consumption of heparin has grown at a rapid pace over the past few years. Moreover, ban of Chinese APIs due to adulterated issue leading to over 100 deaths in the U.S., has drastically attracted new players in heparin processing and manufacturing business. For instance in 2013, German meat company Tönnies group acquired heparin API manufacturer Pharma Action which proposed to manufacture 30...